Fangzhou Inc. Announces Inclusion of Its Shares in Hang Seng Hong Kong-Listed Biotech Index
Fangzhou Inc. Announces Inclusion of Its Shares in Hang Seng Hong Kong-Listed Biotech Index
HONG KONG, Dec. 3, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company's Ordinary Shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), will be included in the Hang Seng Hong Kong-Listed Biotech Index ("HSHKBIO"), effective December 9th, 2024, according to the announcement issued by Hang Seng Indexes Company Limited ("HSIL").
()
香港，2024年12月3日 /PRNewswire/ -- 方舟健客(臨時代碼)（"方舟"或"公司"）（06086.HK），互聯網醫療保健解決方案的領導者，今日宣佈，根據恒生指數有限公司（"HSIL"）發佈的公告，公司在香港聯合交易所（"香港交易所"）的普通股將於2024年12月9日起被納入恒生香港上市生物科技指數（"HSHKBIO"）
()
Mr. Xie Fangmin, Chairman and CEO of Fangzhou, stated, "We are thrilled to be included in the Hang Seng Hong Kong-Listed Biotech Index. This inclusion will not only elevate the company's profile among a broader spectrum of investors, but also create opportunities for our customers, partners, and investors to engage with Fangzhou Inc.'s innovative Internet healthcare solutions and be part of our mission to enhance healthcare accessibility and delivery."
方舟的董事長兼首席執行官謝芳敏表示："我們很高興被納入恒生香港上市生物科技指數。這一納入不僅將提升公司在更廣泛投資者中的知名度，還將爲我們的客戶、合作伙伴和投資者創造與方舟健客的創新互聯網醫療保健解決方案互動的機會，併成爲我們提升醫療保健可及性和服務能力使命的一部分。"
Fangzhou has been listed on the main board of the Hong Kong Stock Exchange since July 2024. As a pioneer in the Internet hospital sector, the Company is focused on chronic disease management and providing tailored medical care and precision medicine for a growing population of chronic disease patients.
方舟自2024年7月起已在香港股票交易所的主板上市。作爲互聯網醫院行業的先驅，公司專注於慢性病管理，提供量身定製的醫療保健和精準醫學，以服務日益增長的慢性病患者群體。
About Hang Seng Hong Kong-Listed Biotech Index ("HSHKBIO")
關於恒生香港上市生物科技指數（"HSHKBIO"）
In 2019 HSIL launched the Hang Seng Hong Kong Listed Biotech Index, which reflects the overall performance of biotech companies that are listed in Hong Kong, including stocks listed through Chapter 18A of the Listing Rules of Stock Exchange of Hong Kong Limited. HSHKBIO includes the 50 largest companies that are classified as "Biotechnology", "Pharmaceuticals", and "Medical Devices" in the Hang Seng Industry Classification System ("HSICS").
2019年，HSIL推出了恒生香港上市生物科技指數，該指數反映在香港上市的生物科技公司的整體表現，包括通過香港聯合交易所上市規則第18A章上市的股票。HSHKBIO包括在恒生行業分類系統（"HSICS"）中被歸類爲"生物技術"、"製藥"和"醫療設備"的50家公司。
About Fangzhou Inc.
關於方舟健客(臨時代碼)。
Fangzhou Inc. (06086.HK) is China's leading online chronic disease management platform. With 45.6 million registered users and 217,000 registered doctors on its platform (as of June 30, 2024), the Company provides tailored medical care and precision medicine for a growing population of chronic disease patients. For more details, visit .
方舟健客(臨時代碼)（06086.HK）是中國領先的在線慢性病管理平台。截止到2024年6月30日，平台上擁有4560萬註冊用戶和217,000名註冊醫生，公司爲日益增長的慢性病患者提供定製的醫療保健和精準醫療服務。更多詳情，請訪問。
Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
媒體聯繫
如需進一步詢問或面試，請聯繫方式：
趙星偉 公共關係副主任
郵箱: pr@jianke.com
Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements
免責聲明：本新聞稿包含前瞻性聲明。實際結果可能因各種因素與預期存在重大差異。提醒讀者不要過於依賴這些聲明。
